US 12,011,439 B2
Combination therapy using C—C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors
Shijie Li, Los Altos, CA (US); Venkat Reddy Mali, Cupertino, CA (US); Rajinder Singh, Belmont, CA (US); Ju Yang, Palo Alto, CA (US); and Penglie Zhang, Foster City, CA (US)
Assigned to CHEMOCENTRYX, INC., Thousand Oaks, CA (US)
Filed by CHEMOCENTRYX, INC., San Carlos, CA (US)
Filed on Aug. 16, 2022, as Appl. No. 17/820,179.
Application 17/820,179 is a continuation of application No. 16/553,339, filed on Aug. 28, 2019, granted, now 11,446,289.
Claims priority of provisional application 62/771,853, filed on Nov. 27, 2018.
Claims priority of provisional application 62/724,412, filed on Aug. 29, 2018.
Prior Publication US 2023/0097128 A1, Mar. 30, 2023
Int. Cl. A61K 31/4545 (2006.01); A61K 31/165 (2006.01); A61K 31/357 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/4545 (2013.01) [A61K 31/165 (2013.01); A61K 31/357 (2013.01); A61K 39/39541 (2013.01); A61P 35/00 (2018.01)] 10 Claims
 
1. A method of treating colon cancer in a human, said method comprising administering an effective amount of a small molecule C-C Chemokine Receptor 4 (CCR4) inhibitor and an anti-CTLA-4 antibody,
wherein the CCR4 inhibitor has the following formula (If)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein
R1 is halogen;
each R2 is halogen;
R4 is hydrogen;
Q is N;
R6 is alkylene-C(O)ORa;
wherein
Ra is hydrogen; and
R7 is absent.